PDCD1 and cancer: Drugs that mediate ICB by targeting the inhibitory receptors CTLA-4 and PD-1 (Figure 2inset panel) have been shown to induce durable responses in subsets of patients with various types of cancer including melanoma, NSCLC, and renal cell cancer (RCC) (187–190).